Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029549013> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3029549013 abstract "5042 Background: Most pts with bladder cancer will be treated with immunotherapy. There is concern for increased TE risk with CPIs in this already high risk population. We present the first analysis of the incidence and outcomes of venous (VTE) and arterial (ATE) thromboembolism in pts with bladder cancer treated with CPIs. Methods: Consecutive pts with bladder cancer treated with CPIs at the Cleveland Clinic from 1/2015 to 12/2019 were identified and TE events noted. Overall survival (OS) was estimated using Kaplan-Meier method and the impact of VTE on OS was evaluated using Cox proportional hazards regression. Results: Of 274 pts, 72% were men (median age 73.3 years, 89% white), 82% had pure UC, 92% had lower tract disease, and 67% had a Bajorin score ≥1 (median KPS 90, 61% visceral metastases), 59% had prior systemic therapy (median 1, range 0-4) and 36% had prior TE (14% ATE, 19% VTE, 0.4% both). At CPI initiation, 24% were on antiplatelet therapy, and 15% on therapeutic anticoagulation. CPI (median doses 5, range 8.5-59) included: 40% atezolizumab, 3% nivolumab, 57% pembrolizumab. VTE occurred in 14% (n = 37), including 8% DVT, 4% PE, 2% both. DVT locations were 56% lower limb, 26% upper limb, 15% visceral vein, 4% visceral+upper limb. 2% (n = 5) had ATE (1% CVA, 0.4% visceral, 0.4% left subclavian). 92% of VTE and all ATE occurred within 6 months of CPI initiation. The incidence of TE was 10.9% (95%CI 6.6%—15.1%) at 6 months and 19.8% (95%CI 13.3%-26.4%) at 12 months. 82% of VTE (mean 6 days) and all ATE (mean 5 days) resulted in hospitalization. Multivariate analysis showed TE (HR 2.296, 95%CI 1.451-3.632, p = 0.0004), Bajorin score 1 (HR 1.490, 95%CI 1.036-2.142, p = 0.0315), and Bajorin score 2 (HR 3.50, 95%CI 2.14-5.74, p < 0.0001) were independently associated with worse OS. Conclusions: CPIs in bladder cancer pts are associated with a high TE risk, especially within six months of initiation. TE is associated with worsened survival. Further investigation into the risk factors for CPI-associated TE is needed to identify if benefits exist from thromboprophylaxis." @default.
- W3029549013 created "2020-06-05" @default.
- W3029549013 creator A5017229890 @default.
- W3029549013 creator A5017302019 @default.
- W3029549013 creator A5024482335 @default.
- W3029549013 creator A5031016267 @default.
- W3029549013 creator A5031818284 @default.
- W3029549013 creator A5037174103 @default.
- W3029549013 creator A5037531240 @default.
- W3029549013 creator A5039576853 @default.
- W3029549013 creator A5057402683 @default.
- W3029549013 creator A5087463997 @default.
- W3029549013 date "2020-05-20" @default.
- W3029549013 modified "2023-10-06" @default.
- W3029549013 title "Thromboembolism (TE) in patients (pts) with bladder cancer treated with checkpoint inhibitors (CPIs)." @default.
- W3029549013 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.5042" @default.
- W3029549013 hasPublicationYear "2020" @default.
- W3029549013 type Work @default.
- W3029549013 sameAs 3029549013 @default.
- W3029549013 citedByCount "0" @default.
- W3029549013 crossrefType "journal-article" @default.
- W3029549013 hasAuthorship W3029549013A5017229890 @default.
- W3029549013 hasAuthorship W3029549013A5017302019 @default.
- W3029549013 hasAuthorship W3029549013A5024482335 @default.
- W3029549013 hasAuthorship W3029549013A5031016267 @default.
- W3029549013 hasAuthorship W3029549013A5031818284 @default.
- W3029549013 hasAuthorship W3029549013A5037174103 @default.
- W3029549013 hasAuthorship W3029549013A5037531240 @default.
- W3029549013 hasAuthorship W3029549013A5039576853 @default.
- W3029549013 hasAuthorship W3029549013A5057402683 @default.
- W3029549013 hasAuthorship W3029549013A5087463997 @default.
- W3029549013 hasConcept C120665830 @default.
- W3029549013 hasConcept C121332964 @default.
- W3029549013 hasConcept C121608353 @default.
- W3029549013 hasConcept C126322002 @default.
- W3029549013 hasConcept C126894567 @default.
- W3029549013 hasConcept C141071460 @default.
- W3029549013 hasConcept C207103383 @default.
- W3029549013 hasConcept C2777701055 @default.
- W3029549013 hasConcept C2780030458 @default.
- W3029549013 hasConcept C2780057760 @default.
- W3029549013 hasConcept C2780352672 @default.
- W3029549013 hasConcept C2908647359 @default.
- W3029549013 hasConcept C44249647 @default.
- W3029549013 hasConcept C50382708 @default.
- W3029549013 hasConcept C61511704 @default.
- W3029549013 hasConcept C71924100 @default.
- W3029549013 hasConcept C90924648 @default.
- W3029549013 hasConcept C99454951 @default.
- W3029549013 hasConceptScore W3029549013C120665830 @default.
- W3029549013 hasConceptScore W3029549013C121332964 @default.
- W3029549013 hasConceptScore W3029549013C121608353 @default.
- W3029549013 hasConceptScore W3029549013C126322002 @default.
- W3029549013 hasConceptScore W3029549013C126894567 @default.
- W3029549013 hasConceptScore W3029549013C141071460 @default.
- W3029549013 hasConceptScore W3029549013C207103383 @default.
- W3029549013 hasConceptScore W3029549013C2777701055 @default.
- W3029549013 hasConceptScore W3029549013C2780030458 @default.
- W3029549013 hasConceptScore W3029549013C2780057760 @default.
- W3029549013 hasConceptScore W3029549013C2780352672 @default.
- W3029549013 hasConceptScore W3029549013C2908647359 @default.
- W3029549013 hasConceptScore W3029549013C44249647 @default.
- W3029549013 hasConceptScore W3029549013C50382708 @default.
- W3029549013 hasConceptScore W3029549013C61511704 @default.
- W3029549013 hasConceptScore W3029549013C71924100 @default.
- W3029549013 hasConceptScore W3029549013C90924648 @default.
- W3029549013 hasConceptScore W3029549013C99454951 @default.
- W3029549013 hasLocation W30295490131 @default.
- W3029549013 hasOpenAccess W3029549013 @default.
- W3029549013 hasPrimaryLocation W30295490131 @default.
- W3029549013 hasRelatedWork W12011 @default.
- W3029549013 hasRelatedWork W12944646 @default.
- W3029549013 hasRelatedWork W13952967 @default.
- W3029549013 hasRelatedWork W16536396 @default.
- W3029549013 hasRelatedWork W20038304 @default.
- W3029549013 hasRelatedWork W2042150 @default.
- W3029549013 hasRelatedWork W3320369 @default.
- W3029549013 hasRelatedWork W5095275 @default.
- W3029549013 hasRelatedWork W5196601 @default.
- W3029549013 hasRelatedWork W7774475 @default.
- W3029549013 isParatext "false" @default.
- W3029549013 isRetracted "false" @default.
- W3029549013 magId "3029549013" @default.
- W3029549013 workType "article" @default.